- Home
- AIM vs POAI Comparison
AIM vs POAI Comparison
Compare AIM & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIM
- POAI
- Stock Information
- Founded
- AIM 1966
- POAI 2002
- Country
- AIM United States
- POAI United States
- Employees
- AIM N/A
- POAI N/A
- Industry
- AIM Biotechnology: Biological Products (No Diagnostic Substances)
- POAI Industrial Specialties
- Sector
- AIM Health Care
- POAI Health Care
- Exchange
- AIM Nasdaq
- POAI Nasdaq
- Market Cap
- AIM 9.8M
- POAI 9.7M
- IPO Year
- AIM N/A
- POAI N/A
- Fundamental
- Price
- AIM $0.14
- POAI $1.45
- Analyst Decision
- AIM Strong Buy
- POAI Hold
- Analyst Count
- AIM 2
- POAI 1
- Target Price
- AIM $2.75
- POAI N/A
- AVG Volume (30 Days)
- AIM 1.5M
- POAI 483.7K
- Earning Date
- AIM 04-01-2025
- POAI 03-27-2025
- Dividend Yield
- AIM N/A
- POAI N/A
- EPS Growth
- AIM N/A
- POAI N/A
- EPS
- AIM N/A
- POAI N/A
- Revenue
- AIM $190,000.00
- POAI $1,484,223.00
- Revenue This Year
- AIM N/A
- POAI N/A
- Revenue Next Year
- AIM $1,693.10
- POAI $569.48
- P/E Ratio
- AIM N/A
- POAI N/A
- Revenue Growth
- AIM N/A
- POAI N/A
- 52 Week Low
- AIM $0.12
- POAI $0.55
- 52 Week High
- AIM $0.62
- POAI $3.67
- Technical
- Relative Strength Index (RSI)
- AIM 36.62
- POAI 50.83
- Support Level
- AIM $0.12
- POAI $1.39
- Resistance Level
- AIM $0.21
- POAI $1.97
- Average True Range (ATR)
- AIM 0.02
- POAI 0.14
- MACD
- AIM -0.00
- POAI -0.02
- Stochastic Oscillator
- AIM 22.88
- POAI 14.88
About AIM AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.